A Regimen for HCV-Infected Patients Who Fail Direct-Acting Antiviral Therapy

Combination fixed-dose sofosbuvir-velpatasvir plus GS-9857 was highly effective in phase II studies.

Although infrequently, direct-acting antiviral agents (DAAs) fail in treating chronic hepatitis C virus (HCV) infection and treatment-induced resistance can develop. Treatment options are limited for this population.

In companion phase II, industry-funded studies, researchers evaluated the safety and efficacy of daily triple therapy with sofosbuvir (an NS5B inhibitor; 400 mg), velpatasvir (a second-generation NS5A inhibitor with a high barrier to resistance; 100 mg), and GS-9857 (an investigational, next-generation NS3/4A protease inhibitor; 100 mg) in treatment-naive and treatment-experienced (i.e., previously failed DAAs) patients with HCV genotypes 1–6 infections.

In one open-label trial involving 197 HCV genotype 1 patients, all treatment…

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

A Regimen for HCV-Infected Patients Who Fail Direct-Acting Antiviral Therapy

Topics

Reviewing Author